Article

Generalized eruptive keratoacanthomas of Grzybowski treated with isotretinoin.

Presbyterian- St. Luke's Hospital, Denver, CO, USA.
Journal of drugs in dermatology: JDD (Impact Factor: 1.32). 12/2008; 7(11):1069-71.
Source: PubMed

ABSTRACT Generalized eruptive keratoacanthomas of Grzybowski is a rare condition of unknown etiology. The disease is characterized by the abrupt onset of many small crateriform papules on the skin and mucous membranes. The authors report of a man with multiple eruptive keratoacanthomas of Grzybowski who responded favorably to oral isotretinoin therapy. After 2 years of follow-up, a complete regression of all lesions was observed, and this rapid clearance under isotretinoin therapy is intriguing with regard to the possible etiology of the condition.

0 Bookmarks
 · 
67 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: The initial patient with generalized eruptive keratoacanthomas was described by Grzybowski in 1950. The condition presents as hundreds to thousands of small (1-5 mm), flesh-colored to erythematous papules. To review the clinical characteristics and treatments of generalized eruptive keratoacanthomas of Grzybowski. We retrospectively reviewed the medical literature using PubMed, searching the terms "eruptive," "generalized," "Grzybowski," "keratoacanthoma," and "multiple." Patient reports and previous reviews of the subject were critically assessed and the salient features presented to the best of our knowledge. Generalized eruptive keratoacanthomas of Grzybowski typically present in the fifth to seventh decades of life and display an equal preponderance for both men and women. The keratoacanthomas are pruritic and predominately appear in sun-exposed regions, such as the face (in which they often demonstrate the sign of Zorro) and the upper trunk; the tumors also show a predilection for intertriginous areas. Topical, intralesional, and systemic treatment modalities have been used; oral retinoids are considered the preferred method of treatment. Generalized eruptive keratoacanthomas of Grzybowski is a rare form of keratoacanthoma and is considered a serious condition because the eruptions are diffuse, persistent, and recurrent. Constant pruritus, ectropion, visceral neoplasms, and unsatisfactory response to treatment are ominous prognostic factors. Successful management of this condition has been observed in patients treated with systemic retinoids, such as acitretin.
    International journal of dermatology 12/2013; 53(2). DOI:10.1111/ijd.12318 · 1.23 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Generalized eruptive keratoacanthoma (GEKA) of Grzybowski is a sporadically occurring, extremely rare variant of keratoacanthoma characterized clinically by severely pruritic, generalized eruption of numerous small follicular papules, often with a central keratotic plug, and histologically by typical features of solitary keratoacanthoma. Despite the continuous addition of new case reports, no definite diagnostic criteria have been established, and an optimum treatment is not yet determined. Herein, we review the different aspects of this rare entity, including pathogenesis, clinical and histopathological features, differential diagnosis, course and prognosis. Different therapeutic approaches and their impact on the course and prognosis of the disease are also evaluated and presented. We propose two sets of diagnostic criteria to define the disease more precisely and to avoid overlapping and confusion with other types of multiple keratoacanthoma. The first set comprises constant clinical and histopathological features that almost always present in every case and the second set includes variable features that were reported in some patients, and to which any emerging finding could be added to avoid missing cases. Although different therapeutic options have been used, either as single agents or in combinations, there is no standard therapy for GEKA and the disease still represents a therapeutic challenge.
    Journal of the European Academy of Dermatology and Venereology 08/2013; DOI:10.1111/jdv.12226 · 2.69 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: : As of 2013, keratoacanthomas (KAs) have not been decided on as either a benign or a malignant entity. Originally considered benign epidermal growths, the assertion by Hodak, Jones, and Ackerman that these lesions are truly "an expression of squamous cell carcinoma" (SCC) fueled the controversy and placed some of the biggest names in the field on opposite sides of the issue. Without a clear understanding of the etiology of KAs and without stringent diagnostic criteria, the literature in regard to KA contains scant reports of their "metastatic potential." Four hundred forty-five cases of KA with reported follow-up and outcomes were reviewed from 113 published articles. In our data set, none of these cases resulted in death or distant metastases. When compared with 429 cases of SCC of the skin, with 61 cases of metastases and 24 deaths as a direct result of SCC, the biologic behavior of the 2 entities is distinct and evident. KAs are benign epidermal growths and not a malignant variant of SCC.
    The American Journal of dermatopathology 12/2013; 36(5). DOI:10.1097/DAD.0000000000000031 · 1.30 Impact Factor